The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Ezra Cohen on Siltuximab Combinations in Head and Neck Squamous Cell Carcinoma

Ezra Cohen, MD
Published Online:10:51 PM, Thu March 3, 2016

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses a recent study looking at integrating siltuximab into two different chemotherapy radiation platforms. The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel. Cohen says patients were initially given the triplet, and then randomized to either the FHX regimen and a cisplatin radiation approach.

Cohen says patients with HPV-negative recurrent and/or metastatic head and neck squamous cell carcinoma did remarkably well, especially on the FHX regimen. He adds that combining siltuximab with other agents may be the key to evoking this sot of response in patients in the future.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.